Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00655915 · ClinicalTrials.gov registry record
Corticosteroid Injection as a Predictor of Outcome in Carpal Tunnel Release
A clinical trial, sponsored by Vanderbilt University.
- Terminated
- Registry status
- 200
- Enrollment target
NCT00655915 is a clinical trial that was terminated before completion, run by Vanderbilt University. The registered enrollment target is 200 participants.
The verdict
NCT00655915 was terminated before completion, sponsored by Vanderbilt University.
- TERMINATED
- Registry status
- 200 participants
- Enrollment target
Study Summary
This study will investigate whether symptomatic improvement following carpal tunnel corticosteroid injection can be correlated to symptomatic improvement following carpal tunnel release and therefore serve as a prognostic indicator. Clinical question: Does response to corticosteroid injection in CTS predict outcomes of surgical treatment? Secondary Questions: 1. Can we confirm previous retrospectively collected data that a certain percentage of conservatively managed patients with steroid injection will avoid surgery, and that patients who undergo surgery will have better outcomes than those who do not. 2. Are there differences between worker's compensation and non-worker's compensation patients with regard to the primary clinical question? 3. What are Carpal Tunnel Release outcomes for the subset of patients with negative electrophysiologic studies? 4. What are the outcomes of patients who undergo carpal tunnel release vs. those who choose not to undergo carpal tunnel release? A prospective cohort design study is the appropriate study design in order to measure the association between a predictor (response to injection) and outcome (response to surgery).
Interventions
- OTHER Corticosteroid Injection- 1ml of Betamethasone and 1 ml of 1% Lidocaine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00655915
The ClinicalTrials.gov registry entry for NCT00655915 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Corticosteroid Injection- 1ml of Betamethasone and 1 ml of 1% Lidocaine is the first listed.
NCT00655915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00655915 about?
NCT00655915 is a clinical study titled "Corticosteroid Injection as a Predictor of Outcome in Carpal Tunnel Release". This study will investigate whether symptomatic improvement following carpal tunnel corticosteroid injection can be correlated to symptomatic improvement following carpal tunnel release and therefore serve as a prognostic indicator. Clinical question: Does response to corticosteroid injection in CT...
What is the current status of trial NCT00655915?
This trial is currently terminated. The enrollment target is 200 participants. The study started on 2007-12. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00655915?
The interventions under investigation include: Corticosteroid Injection- 1ml of Betamethasone and 1 ml of 1% Lidocaine (OTHER).
Who is sponsoring clinical trial NCT00655915?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.